Side effects largely follow the molecule, so gastrointestinal reactions and the labeled warnings apply to both routes. What differs is the information wrapped around them. Brand tirzepatide is FDA-approved and carries a reviewed label, a boxed warning and defined reporting duties. Compounded tirzepatide is not FDA-approved, and the agency does not review it for safety, effectiveness or quality.
The label that exists on one side and not the other
Approved tirzepatide labeling opens with a boxed warning about thyroid C-cell tumors seen in rats at clinically relevant exposures, notes that human relevance has not been determined, and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Labeled warnings and precautions cover severe gastrointestinal reactions, with use not recommended in severe gastroparesis, plus acute kidney injury from volume depletion, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia when used alongside insulin or an insulin secretagogue, diabetic retinopathy complications in type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation.
The most common adverse reactions listed at 5 percent or higher are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease. In SURMOUNT-1, gastrointestinal events were mostly mild to moderate and clustered during dose escalation, and adverse events led to discontinuation in 4.3 percent, 7.1 percent and 6.2 percent of participants across the three tirzepatide doses against 2.6 percent on placebo.
None of that documentation is guaranteed to arrive with a compounded vial, because a compounded label is not FDA-reviewed and FDA has noted that labels on compounded drugs may omit important information such as adequate directions for safe use.
What the reporting data shows, and what it cannot
FDA has published running counts of adverse event reports tied to compounded versions of these drugs. As of May 31, 2026, the agency had received 990 reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes two things about those figures that pull in opposite directions: many of the reported events appear consistent with events seen with the approved versions, and federal law does not require state-licensed pharmacies outside the outsourcing facility category to submit adverse events to FDA, so the totals are likely to understate reality.
A published pharmacovigilance analysis of the FDA Adverse Event Reporting System from 2018 to 2024 identified 707 compounded-product reports among 81,078 GLP-1 receptor agonist reports. Compounded formulations showed higher reporting odds ratios for preparation errors, contamination, compounding and manufacturing issues, abdominal pain, diarrhea, nausea, cholecystitis and suicidality, along with higher odds of hospitalization. The same analysis found lower reporting odds for administration and dosing errors. Disproportionality analysis of spontaneous reports cannot establish incidence or causation, and the honest reading is a signal about product quality problems rather than a measured rate.
| Monitoring topic | Approved product | What to establish for a compounded preparation |
|---|---|---|
| Concentration | Fixed strength per presentation | Stated concentration and how the dose is measured |
| Thyroid history | Boxed warning and contraindication on label | That the prescriber screened for it |
| Gastrointestinal reactions | Labeled, with escalation guidance | Who to contact and how quickly |
| Pancreatitis and gallbladder | Labeled warnings with stopping advice | Written instructions for symptoms |
| Hypoglycemia risk | Addressed for insulin and secretagogue use | Whether other diabetes drugs were reviewed |
| Reporting a problem | Manufacturer and FDA MedWatch routes | Named pharmacy and a route to FDA |
Concentration uncertainty is the compounded-specific risk
The distinctive hazard in this tier is not a new side effect. It is receiving more drug than intended. FDA has described reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable products, including patients measuring incorrect doses and clinicians miscalculating them. It has also described reports involving doses beyond what appears on the approved label, whether through larger single doses, more frequent dosing, or faster escalation.
A poison control case series illustrates the mechanism. Three patients who obtained compounded semaglutide from compounding pharmacies or an aesthetic spa experienced adverse events after incorrect administration, two of them involving ten-fold dosing errors, with one patient dosing in milliliters and units rather than milligrams. The authors note that vials supplied with syringes lack the safety features built into prefilled manufactured pens. That format difference is the practical reason label numbers from an approved product cannot be carried across to a compounded vial.
One related point is often stated inaccurately. FDA’s warning about salt forms names semaglutide sodium and semaglutide acetate as different active ingredients from those in the approved drugs. That warning is scoped to semaglutide, and there is no equivalent FDA-named tirzepatide salt to point at.
Verifying the stated concentration before the first dose is the check that most reduces this risk, and programs differ in how openly they publish it. Cash providers such as HealthRX, Henry Meds, Ro, and Hims and Hers each set out their own terms for compounded tirzepatide, while a manufacturer channel like LillyDirect lists only the approved product at fixed strengths. A number on the label is useful only when a patient can trace it back to the pharmacy that assigned it.
Storage, shipping and the questions worth asking
Injectable GLP-1 products require refrigeration as set out in their package inserts, and FDA has received complaints that some compounded products arrived warm or with inadequate ice packs, recommending that patients not use a product that arrives that way. Temperature is one of the few quality variables a patient can actually check on arrival, which makes it worth checking every time.
Supervision is the other variable that separates programs. A practice that names its prescriber and its dispensing pharmacy, and that keeps a clinician reachable after shipment, is structurally different from a seller that ships after a form. Henry Meds and FormBlends are among the cash-pay practices that publish that structure, and the larger telehealth operators such as Ro and Hims and Hers do so in their own terms. FDA’s own warning signs point the same way, listing companies that ship without screening and a prescription from a licensed doctor and companies with no clinician available afterward.
Frequently asked questions
Are side effects worse with compounded tirzepatide?
The pharmacology is the same, so the expected reaction profile is the same. Reporting data suggests more product quality and preparation problems in the compounded tier, and dosing errors are a documented hazard with vial-and-syringe formats. Severity therefore depends more on preparation accuracy than on any difference in the peptide itself.
What symptoms should prompt contact rather than waiting?
Labeled warnings single out severe or persistent abdominal pain, which may signal pancreatitis or gallbladder disease, signs of dehydration with reduced urine output, and symptoms of a serious allergic reaction. Persistent vomiting that prevents fluid intake also belongs in that group because volume depletion drives the kidney risk.
Does a compounded product need different monitoring?
It needs the same clinical monitoring plus verification the approved product does not require: the stated concentration, how the dose is measured, the beyond-use date, and the name of the pharmacy that prepared it. Those checks address preparation risk rather than pharmacological risk.
How are problems reported for each route?
Adverse reactions with approved products can be reported to the manufacturer or to FDA through MedWatch. For compounded products the same FDA route is available, but state-licensed pharmacies that are not outsourcing facilities have no federal duty to submit reports, so patient-initiated reporting carries more weight.
